Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP

International Journal of Hematology

Volumn 100, Issue 6, 2014, Pages 554-558

  Hayashi, Toshiaki ^a   Ikeda, Hiroshi ^a   Igarashi, Tetsuyuki ^a   Maruyama, Yumiko ^a   Aoki, Yuka ^a   Nojima, Masanori ^b   Ishida, Tadao ^a   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Autologous stem cell transplantation (ASCT); B type natriuretic peptide (BNP); Dose adjusted melphalan; Immunoglobulin light chain (AL) amyloidosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; MELPHALAN; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; HEART EJECTION FRACTION; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; ADVERSE EFFECTS; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AMYLOIDOSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84916877273     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1680-1     Document Type: Article

References (17)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.
2. Kyle R, Gertz M, Greipp P. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.
3. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960–3.
4. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–9.
5. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–94.
6. Gertz M, Lacy MQ, Dispenzieri A, Ansell SM, Elliott M, Gastineau DA, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34:1025–31.
7. Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica. 2006;91:1635–43.
8. Gertz M, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79:319–28.
9. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
10. Saito M, Hayashi T, Nojima M, Ikeda H, Tarasawa I, Yasui H, et al. Long-term survival after autologous peripheral blood stem cell transplantation in a patient with primary AL amyloidosis complicating congestive heart failure. Rinsho Ketsueki. 2007;48:1478–83.
11. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48:557–61.
12. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–95.
13. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;87:465–71.
14. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381–8.
15. Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, et al. Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leuk. 2014 (in press). (Published Online: February 17, 2014).
16. Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, et al. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014;12:2.
17. Cibeira MMT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346–52.